Nature Reviews Clinical Oncology http://dx.doi.org/10.1038/nrclinonc.2017.175 (2017)
In the online and PDF versions of this Review, in the 'Acquired resistance' subsection, RETI788N was erroneously written as RETI887N, and the ROS1G2032R mutation was written as ROS1D2033N. This information has now been corrected in the online and PDF versions of the Review.
Additional information
The online version of the original article can be found at 10.1038/nrclinonc.2017.175
Rights and permissions
About this article
Cite this article
Drilon, A., Hu, Z., Lai, G. et al. Erratum: Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 15, 150 (2018). https://doi.org/10.1038/nrclinonc.2017.188
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.188
This article is cited by
-
The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
Journal of Cancer Research and Clinical Oncology (2023)
-
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Nature Cancer (2023)
-
Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
Acta Neuropathologica (2023)
-
A critical ETV4/Twist1/Vimentin axis in Ha-RAS-induced aggressive breast cancer
Cancer Gene Therapy (2022)
-
Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes
Breast Cancer Research and Treatment (2022)
